NCT04154943 Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma Status COMPLETED Phase PHASE2
NCT04050436 Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04046107 Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy Status WITHDRAWN Phase PHASE1/PHASE2
NCT03972657 A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT03969004 Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03916627 Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03889912 Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Status COMPLETED Phase PHASE1
NCT03787095 Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART Status TERMINATED Phase PHASE1/PHASE2
NCT03684785 Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT03669718 A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03580694 Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Status TERMINATED Phase PHASE1
NCT03565783 Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03564340 Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers Status RECRUITING Phase PHASE1/PHASE2
NCT03492489 Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Status NO_LONGER_AVAILABLE Phase N/A
NCT03491683 INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03294083 A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03233139 Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03132636 PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy Status COMPLETED Phase PHASE2